<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03128229</url>
  </required_header>
  <id_info>
    <org_study_id>16-1403</org_study_id>
    <nct_id>NCT03128229</nct_id>
  </id_info>
  <brief_title>Diabetic Kidney Alarm (DKA) Study</brief_title>
  <acronym>DKA</acronym>
  <official_title>Diabetic Kidney Alarm (DKA) Study - Tubulopathy in New Onset Diabetic Ketoacidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado Denver School of Medicine Barbara Davis Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado Denver School of Medicine Barbara Davis Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goals of this study are to determine whether tubular dysfunction (elevated
      urine sodium, bicarbonate and amino acids) and injury (elevated kidney injury molecule 1
      [KIM-1], neutrophil gelatinase-associated lipocalin [NGAL] and matrix metallopeptidase 9
      [MMP9]) exist in new onset diabetic ketoacidosis (age 3-18), whether it is reversible and
      whether it is related to uricosuria and copeptin. The investigators propose to study a cohort
      of youth (ages 3-18, n=40) with new onset T1D who have serum and urine collection at DKA
      diagnosis and 3-month follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every year over 86,000 children (0-14 years) worldwide are diagnosed with type 1 diabetes
      (T1D) translating to a lifetime of exposure and risk for early death from cardiovascular
      disease (CVD) and diabetic kidney disease (DKD). DKD, which manifests in children and
      adolescents, remains the leading cause of renal failure and dialysis in the Western world
      (4). While diabetic glomerulopathy has received significant attention from researchers,
      determinants of tubular injury in diabetes are less well examined. Compared to glomerular
      injury, tubular injury is known to associate better with renal function. The majority of
      youth diagnosed with T1D in the US present with diabetic ketoacidosis (DKA), a condition
      associated with risks factors for tubular injury including dehydration, metabolic acidosis
      and acute glycemia. It is unknown whether DKA is associated with tubular injury. The
      investigators published the first report showing that youth with established T1D have more
      acidic urine and higher fractional excretion of uric acid (FeUA) than their non-diabetic
      peers, which may predispose to UUA-mediated tubulopathy. Furthermore, T1D is associated with
      vasopressin overactivity, and the investigators reported strong relationships between serum
      copeptin, a reliable surrogate marker for vasopressin, and DKD in T1D. The overarching goals
      of this study are to determine whether tubular dysfunction (elevated urine sodium,
      bicarbonate and amino acids) and injury (elevated KIM-1, NGAL and MMP9) exist in new onset
      DKA, whether it is reversible and whether it is related to uricosuria and copeptin. The
      investigators propose to study a cohort of youth (ages 3-18, n=40) with new onset T1D who
      have serum and urine collection at DKA diagnosis and 3-month follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proximal tubular dysfunction</measure>
    <time_frame>At DKA (0-8 and 12-24 hours after starting IV insulin)</time_frame>
    <description>Change in urine Na, HCO3 and amino acids concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proximal tubular injury</measure>
    <time_frame>At DKA (0-8 and 12-24 hours after starting IV insulin)</time_frame>
    <description>Change in urine and serum NGAL, KIM-1 and MMP9 concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proposed mediators of tubular dysfunction and injury</measure>
    <time_frame>At DKA (0-8 and 12-24 hours after starting IV insulin)</time_frame>
    <description>Change in urine uric acid and serum fructose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proposed mediators of tubular dysfunction and injury</measure>
    <time_frame>At DKA (0-8 hours after starting IV insulin)</time_frame>
    <description>Presence of urine uric acid crystals by polarized microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proposed mediators of tubular dysfunction and injury</measure>
    <time_frame>At DKA (12-24 hours after starting IV insulin)</time_frame>
    <description>Presence of urine uric acid crystals by polarized microscopy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Diabetic Ketoacidosis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and urine collection at 0-8h and 12-24h after starting IV insulin, and at 3 month
      follow-up.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants (3-18 years) with new onset T1D presenting with DKA will be recruited from the
        Emergency Department (ED) at Children's Hospital Colorado.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New onset T1D

          -  DKA (mild, moderate and severe DKA eligible)

          -  3-17 years of age

          -  Toilet trained

          -  Boys and girls

          -  All ethnicities

          -  Initial presentation to Children's Hospital Colorado (CHCO) Main ED

        Exclusion Criteria:

          -  Known T1D

          -  Non-T1D etiology

          -  History of chronic kidney disease (eGFR &lt;60ml/min/1.73m2) or dialysis dependent

          -  History of tubulopathy (e.g. Fanconi syndrome)

          -  Currently menstruating

          -  Patient visiting Colorado with plan to establish diabetes care outside of Colorado

          -  On ACE-inhibitors or angiotensin II-receptor blockers (ARB)

          -  On sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Petter Bjornstad, M.D.</last_name>
    <phone>7207774659</phone>
    <email>petter.bjornstad@childrenscolorado.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80238</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Bjornstad, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Petter Bjornstad, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Nadeau, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bjornstad P, Johnson RJ, Snell-Bergeon JK, Pyle L, Davis A, Foster N, Cherney DZ, Maahs DM. Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: A brief report from the T1D exchange Biobank. J Diabetes Complications. 2017 Feb;31(2):387-389. doi: 10.1016/j.jdiacomp.2016.11.015. Epub 2016 Dec 7.</citation>
    <PMID>27979439</PMID>
  </reference>
  <reference>
    <citation>Bjornstad P, Maahs DM, Jensen T, Lanaspa MA, Johnson RJ, Rewers M, Snell-Bergeon JK. Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. J Diabetes Complications. 2016 Aug;30(6):1093-6. doi: 10.1016/j.jdiacomp.2016.04.012. Epub 2016 Apr 19.</citation>
    <PMID>27141815</PMID>
  </reference>
  <reference>
    <citation>Roncal-Jimenez CA, Milagres T, Andres-Hernando A, Kuwabara M, Jensen T, Song Z, Bjornstad P, Garcia GE, Sato Y, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ. Effects of exogenous desmopressin on a model of heat stress nephropathy in mice. Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F418-F426. doi: 10.1152/ajprenal.00495.2016. Epub 2016 Dec 21.</citation>
    <PMID>28003190</PMID>
  </reference>
  <reference>
    <citation>Bakes K, Haukoos JS, Deakyne SJ, Hopkins E, Easter J, McFann K, Brent A, Rewers A. Effect of Volume of Fluid Resuscitation on Metabolic Normalization in Children Presenting in Diabetic Ketoacidosis: A Randomized Controlled Trial. J Emerg Med. 2016 Apr;50(4):551-9. doi: 10.1016/j.jemermed.2015.12.003. Epub 2016 Jan 25.</citation>
    <PMID>26823137</PMID>
  </reference>
  <reference>
    <citation>Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M. Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998-2012. JAMA. 2015 Apr 21;313(15):1570-2. doi: 10.1001/jama.2015.1414.</citation>
    <PMID>25898057</PMID>
  </reference>
  <reference>
    <citation>Dabelea D, Rewers A, Stafford JM, Standiford DA, Lawrence JM, Saydah S, Imperatore G, D'Agostino RB Jr, Mayer-Davis EJ, Pihoker C; SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study. Pediatrics. 2014 Apr;133(4):e938-45. doi: 10.1542/peds.2013-2795. Epub 2014 Mar 31.</citation>
    <PMID>24685959</PMID>
  </reference>
  <reference>
    <citation>Rewers A, Chase HP, Mackenzie T, Walravens P, Roback M, Rewers M, Hamman RF, Klingensmith G. Predictors of acute complications in children with type 1 diabetes. JAMA. 2002 May 15;287(19):2511-8.</citation>
    <PMID>12020331</PMID>
  </reference>
  <reference>
    <citation>Bjornstad P, Roncal C, Milagres T, Pyle L, Lanaspa MA, Bishop FK, Snell-Bergeon JK, Johnson RJ, Wadwa RP, Maahs DM. Hyperfiltration and uricosuria in adolescents with type 1 diabetes. Pediatr Nephrol. 2016 May;31(5):787-93. doi: 10.1007/s00467-015-3299-8. Epub 2015 Dec 23.</citation>
    <PMID>26701836</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado Denver School of Medicine Barbara Davis Center</investigator_affiliation>
    <investigator_full_name>Petter Bjornstad</investigator_full_name>
    <investigator_title>Pediatric Endocrinology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

